Abstract 594P
Background
MET alteration, as promising rare target, plays the key role in the development of NSCLC. However, the treatment pattern and efficacy for Chinese NSCLC patients (pts) with MET alteration in real-world setting is limited. Here, we report the treatment pattern and clinical outcome in Chinese NSCLC pts with MET alteration.
Methods
We performed a retrospective, multicenter study in NSCLC pts with MET alteration between Jul. 2021 and Sep. 2022 in China. Patient characteristics, gene profile, and treatment pattern were collected. The objective response rate (ORR) and time to treatment failure (TTF) were analyzed.
Results
202 NSCLC pts with MET alteration were collected. 117 MET exon 14 skipping mutation (MET ex14m) and MET amplification (amp) (MET NGS GCN≥3.5) pts with subsequent efficacy assessment and follow-up data were included for analysis. The ORR of pts with MET ex14m received 1L savolitinib (savo mono), other MET inhibitor (METi) and chemotherapy (chemo)-based regimen were 56.3%, 16.7%, 36.3%, respectively. The ORR of pts with de novo MET amp received savo, other METi, and chemo-based regimen as 1st-line therapy were 66.7%, 0, 20%, respectively. The ORR of post EGFR/ALK-TKI resistance pts with MET amp (resistant MET amp) received savo mono, savo plus osimertinib (osi), other METi and chemo-based regimen were 12.5%, 43.8%, 0, 14.2%, respectively. (Table) Median TTF of 1L savo mono in pts with MET ex14m was 12.6months and median TTF of savo plus osi in pts with resistant MET amp was 11.3 months. Savo discontinuation due to adverse events occurred in MET ex14m, de novo MET amp and resistant MET amp pts were 18.7%, 33.3%, and 7%, respectively. The safety profile of savo were similar to previously reported data. Table: 594P
The ORR result in the analysis
MET ex14m (n=44) | De novo MET amp (n=16) | Resistant MET amp (n=57) | |||||
n | ORR | n | ORR | n | ORR | ||
1L | Savo | 16 | 56.3% | 3 | 66% | NA | |
Other METi | 6 | 16.7% | 3 | 0% | |||
Chemo | 22 | 36.3% | 10 | 20% | |||
2L+ | Savo | 14 | 42.8% | 2 | 50% | 8 | 12.5% |
Savo+osi | 2 | 50% | 2 | 50% | 32 | 43.8% | |
Other METi | 3 | 0 | 0 | NA | 3 | 0 | |
Chemo | 23 | 26.1% | 14 | 28.5% | 14 | 14.2% |
Conclusions
The real-world analysis results showed the promising clinical benefit of savo in NSCLC pts with MET alterations and the acceptable safety. Follow-up of these pts are still ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract